PRISM BioLab Co.,LTD Cash Flow Statement

Financials in millions JPY. Fiscal year is October - September.

Millions JPY. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022
Net Income	-833.7	-1,050	-526.91	-
Depreciation & Amortization	-	-	8.74	-
Loss (Gain) From Sale of Assets	-	-0.1	0	-
Asset Writedown & Restructuring Costs	82.98	216.78	28.15	-
Stock-Based Compensation	5.47	-	-	-
Other Operating Activities	-26.88	52.1	0.17	-
Change in Accounts Receivable	-	-	21.72	-
Change in Accounts Payable	6.64	19.75	8.23	-
Change in Unearned Revenue	-663.48	886.91	8.69	-
Change in Other Net Operating Assets	-39.39	24.21	-62.6	-
Operating Cash Flow	-1,468	150.14	-513.81	-
Capital Expenditures	-64.7	-205.79	-34.59	-
Sale of Property, Plant & Equipment	-	0.07	-	-
Sale (Purchase) of Intangibles	-2.99	-5.91	-	-
Other Investing Activities	-1.33	-32.56	-5.79	-
Investing Cash Flow	-69.01	-244.19	-40.38	-
Issuance of Common Stock	33.59	3,391	-	-
Other Financing Activities	0	-20.85	-	-
Financing Cash Flow	33.59	3,370	-	-
Foreign Exchange Rate Adjustments	27.34	-17.93	0.14	-
Miscellaneous Cash Flow Adjustments	0	0	-	-
Net Cash Flow	-1,476	3,258	-554.05	-
Free Cash Flow	-1,533	-55.64	-548.4	-
Free Cash Flow Margin	-226.34%	-18.21%	-485.63%	-
Free Cash Flow Per Share	-41.97	-1.78	-19.87	-
Cash Income Tax Paid	1.27	1.25	1.21	-
Levered Free Cash Flow	-1,228	228.53	-357.75	-
Unlevered Free Cash Flow	-1,228	228.53	-357.75	-
Change in Working Capital	-696.23	930.88	-23.96	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.